SHELLI BROWN: Open Payments
NPI 1255058640 · ATLANTIC, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$582 in 42 payments from 9 companies in 2025. Trend: 2023 $749 · 2024 $399 · 2025 $582
Food & beverage: $582
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 22 | $193 |
| Otsuka America Pharmaceutical, Inc. | 5 | $102 |
| Lundbeck LLC | 3 | $61 |
| Neurocrine BioSciences, Inc. | 3 | $59 |
| Janssen Pharmaceuticals, Inc | 2 | $53 |
| E.R. Squibb & Sons, L.L.C. | 2 | $37 |
| Corium, LLC | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: ARISTADA, REXULTI, INGREZZA, INVEGA SUSTENNA, ABILIFY MAINTENA, COBENFY, Azstarys, UZEDY.
Industry payments across IA — which companies pay providers there.
